Since the occurrence of novel coronavirus disease 2019 (COVID-19) pandemic, there have
been many discussions on the repurposing of existing drugs for the treatment of COVID-19 …

This is the largest meta-analysis including critical events and mortality data on patients
prescribed ACEi/ARB and found evidence of beneficial effects of chronic ACEi/ARB use …

Importance The chronic receipt of angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs) has been assumed to exacerbate complications …

With the objective of linking early findings relating to the novel SARS-CoV-2 coronavirus
with potentially informative findings from prior research literature and to promote …

Background and aims The coronavirus disease 2019 (COVID-19) number of death cases is
still increasing. One of the comorbidities associated with severe outcome and mortality of …

Background. Although vaccine rollout for COVID‐19 has been effective in some countries,
there is still an urgent need to reduce disease transmission and severity. We recently carried …

Results The final selected studies (n= 24 studies; 32,715 patients) showed significant
reductions in ICU admission (OR= 0.78, 95% CI: 0.58–1.06; n= 10; I 2= 58.5%) and death …

Introduction Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor
blockers (ARBs) share their target receptor site with the SARS-CoV-2 virus, that may cause …

Background The association of antihypertensive drugs with the risk and severity of COVID-
19 remains unknown. Methods and Results We systematically searched PubMed …

Introduction The use of renin-angiotensin system (RAS) inhibitors, including angiotensin-
converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), was …